See more : Capital Environment Holdings Limited (3989.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Eterna Therapeutics Inc. (ERNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eterna Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- OVB Holding AG (O4B.DE) Income Statement Analysis – Financial Results
- PT Wahana Ottomitra Multiartha Tbk (WOMF.JK) Income Statement Analysis – Financial Results
- Mayr-Melnhof Karton AG (MNHFF) Income Statement Analysis – Financial Results
- MBN Corporation (MBN.TO) Income Statement Analysis – Financial Results
- Acusphere, Inc. (ACUS) Income Statement Analysis – Financial Results
Eterna Therapeutics Inc. (ERNA)
About Eterna Therapeutics Inc.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.00K | 0.00 | 0.00 | 0.00 | 19.81M | 23.34M | 21.27M | 22.31M | 24.52M |
| Cost of Revenue | 236.00K | 497.00K | 459.00K | 98.00K | 7.84M | 8.39M | 7.09M | 8.13M | 13.06M |
| Gross Profit | -168.00K | -497.00K | -459.00K | -98.00K | 11.96M | 14.95M | 14.19M | 14.18M | 11.46M |
| Gross Profit Ratio | -247.06% | 0.00% | 0.00% | 0.00% | 60.40% | 64.07% | 66.68% | 63.55% | 46.74% |
| Research & Development | 5.92M | 10.39M | 12.71M | 3.95M | 26.00K | 72.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 14.59M | 16.84M | 14.72M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.59M | 16.84M | 14.72M | 3.30M | 13.15M | 14.41M | 15.45M | 16.46M | 18.06M |
| Other Expenses | 461.00K | -1.17M | 899.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.97M | 27.23M | 27.43M | 7.25M | 13.18M | 14.49M | 15.59M | 16.46M | 18.06M |
| Cost & Expenses | 21.20M | 27.23M | 27.43M | 7.25M | 21.02M | 22.87M | 22.68M | 24.59M | 31.12M |
| Interest Income | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| Interest Expense | 614.00K | 30.00K | 74.00K | 43.00K | 249.00K | 389.00K | 498.00K | 576.00K | 484.00K |
| Depreciation & Amortization | 1.12M | 497.00K | 459.00K | 98.00K | 3.17M | 2.76M | 2.32M | 2.89M | 3.10M |
| EBITDA | -19.93M | -33.22M | -121.95M | -7.15M | 1.96M | 3.23M | 915.00K | 609.00K | -3.63M |
| EBITDA Ratio | -29,314.71% | 0.00% | 0.00% | 0.00% | 9.88% | 13.83% | 4.30% | 2.73% | -14.26% |
| Operating Income | -21.14M | -33.22M | 68.34M | -7.25M | -1.21M | 464.00K | -1.40M | -2.28M | -6.60M |
| Operating Income Ratio | -31,080.88% | 0.00% | 0.00% | 0.00% | -6.12% | 1.99% | -6.59% | -10.21% | -26.92% |
| Total Other Income/Expenses | -536.00K | 8.68M | -95.05M | -19.28M | -808.00K | -787.00K | 391.00K | -607.00K | -614.00K |
| Income Before Tax | -21.67M | -24.53M | -122.30M | -7.29M | -2.02M | -323.00K | -1.01M | -2.89M | -7.21M |
| Income Before Tax Ratio | -31,869.12% | 0.00% | 0.00% | 0.00% | -10.20% | -1.38% | -4.75% | -12.93% | -29.42% |
| Income Tax Expense | -3.00K | 45.00K | 5.00K | -19.20M | 27.00K | -64.00K | 66.00K | 38.00K | 12.00K |
| Net Income | -21.67M | -24.58M | -122.31M | 11.91M | -2.05M | -259.00K | -1.08M | -2.92M | -7.23M |
| Net Income Ratio | -31,864.71% | 0.00% | 0.00% | 0.00% | -10.34% | -1.11% | -5.06% | -13.10% | -29.47% |
| EPS | -4.08 | -8.06 | -56.49 | 27.08 | -28.48 | -3.85 | -17.64 | -61.44 | -157.26 |
| EPS Diluted | -4.08 | -8.06 | -56.49 | 27.08 | -28.48 | -3.85 | -17.64 | -61.44 | -157.26 |
| Weighted Avg Shares Out | 5.31M | 3.05M | 2.17M | 439.70K | 71.88K | 67.20K | 61.05K | 47.58K | 45.95K |
| Weighted Avg Shares Out (Dil) | 5.31M | 3.05M | 2.17M | 439.70K | 71.88K | 67.20K | 61.05K | 47.58K | 45.95K |
BTX Stock: Over 30% Increase Intraday Explanation
Brooklyn ImmunoTherapeutics Reports Inducement Grants
Brooklyn Immunotherapeutics Stock Price Increased 27.33%: Why It Happened
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning
Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime
Source: https://incomestatements.info
Category: Stock Reports